Vitamin C Trials

For the primary or secondary prevention of CVD, vitamin C has not been well studied in randomized trials. In the Chinese Cancer Prevention Trial, no reduction in cerebrovascular mortality was found among participants assigned a combination of vitamin C (125 mg) and molybdenum (30 |g). The HDL-Atherosclerosis Treatment Study (HATS) and Heart Protection Study (HPS) trials used antioxidant combinations that contained vitamin C, and both studies failed to show a reduction in CVD events. The only large trial of vitamin C alone (500 mg daily) was in one study arm of the WACS, which found no overall effect of vitamin C on CVD outcomes (RR = 1.02; 95% CI, 0.92-1.13).48 The Physicians' Health Study II (PHS II) is the only other large trial with a study arm analyzing vitamin C (500 mg daily) alone, and this trial is scheduled to end in 2007.36

0 0

Post a comment